The story of the cyclooxygenase-2 (COX-2) inhibitors (coxibs) has been a serpiginous one. The initial triumph of the successful development of drugs designed from a clear rational pharmacological design was followed, initially by excessive hype as the drugs came to market, and then subsequent hubris in the face of biological complexity. Now it seems time that celecoxib, as the main remaining drug in the class, is due for reappraisal.
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The discovery of the COX-2 isoform in 1991 1 provided the stimulus to develop drugs that would avoid the harmful upper gastrointestinal (GI) complications (due to COX-1 inhibition), while having the beneficial anti-inflammatory effects (due to inhibition of COX-2). This selective action promised superiority compared with the traditional, nonsteroidal anti-inflammatory agents (NSAIDs), such as ibuprofen, naproxen and indometacin, which were bedevilled by GI complications. The major pharmaceutical companies responded to the discovery of COX-2 and in the early 2000s the first generation of COX-2 selective drugs, subsequently termed the coxibs, rofecoxib and celecoxib, were launched, having been specifically designed to block the active site of COX-2 but not COX-1. Although etodolac and meloxicam, developed as traditional NSAIDs that fortuitously turned out to be moderately COX-2 selective, were already available in many markets, this advancement still proved to be a landmark in rational drug design. The initial promise of the coxibs seemed to be fulfilled, although perhaps less impressively than hoped. Reduced upper GI toxicity was reported in the key licensing trials, 2, 3 although these effects in the population with an average risk were only seen by using a pooled upper GI endpoint including endoscopically detected ulcers, and not necessarily clinical endpoints, such as ulcer complications. 2 The COX-1/COX-2 dichotomy was soon shown to be an oversimplification: it seems that inhibition of both COX-1 and COX-2 are required to induce gastroduodenal ulceration 4 and COX-2 is important in ulcer healing. 5 However, later studies focused on the patients at higher risk of GI complications, namely those who had already suffered a previous peptic ulcer or a peptic ulcer bleed. These confirmed the improved safety profile of celecoxib. In these higher-risk groups, celecoxib was initially shown to be as effective as nonselective NSAIDs combined with a proton pump inhibitor (PPI). [6] [7] [8] Subsequently, celecoxib combined with a PPI was shown to be associated with a much reduced rate of upper GI rebleeding compared with celecoxib alone, confirming this combination to be optimal strategy from the GI safety perspective. 9 Additional data also confirmed that coxibs were associated with a lower incidence of lower GI effects, predominantly chronic bleeding. 8 This apparent significant advantage was then tempered by an increasing body of data showing an increased risk of cardiovascular events associated with rofecoxib, celecoxib and the other coxibs. [10] [11] [12] This evidence was sufficient to lead to the withdrawal of rofecoxib and valdecoxib (lumiracoxib was withdrawn predominantly over additional concerns about hepatotoxicity) and limitations to be placed on the use of celecoxib. The adverse cardiovascular events were attributed to a variety of COX-2-dependent mechanisms including increased vascular tone and blood pressure, altered renal microcirculation and, in particular, unbalanced COX inhibition in the circulatory system. 13 Platelet-derived prothrombotic thromboxane production via COX-1 is normally offset by vascular wall COX-2-mediated antithrombotic prostacyclin (PGI2) production. This was thought to explain the elevated prothrombotic risk associated with coxib use. However, this is also known now to be an oversimplification: physiological COX-2 expression has not been detected in normal endothelium 14 and the physiological PGI2 production in the circulatory system is mediated Time to reappraise the therapeutic place of celecoxib via COX-1. 15 In keeping with this, all nonaspirin NSAIDs and coxibs 12, 16 seem to increase the risk of adverse circulatory outcomes. The relative risks of the different agents are probably more dependent on factors other than just COX-2 inhibition, including pharmacokinetics, tissue penetration, membrane binding and modulation of COX-1 activity. However, these concerns left celecoxib marooned in a small niche as the agent of choice for those at highest risk of GI side effects but without an increased cardiovascular risk. 16 Several recent pieces of information should lead to a reassessment of the role of celecoxib. A large observational study, of real-world outcomes with different agents, showed that rofecoxib seemed to be a significant outlier in terms of increased risk for myocardial infarction (relative risk 1.58; 95% confidence interval [CI] 1.07-2.17) and the risks associated with celecoxib (relative risk 1.24; 95% CI 0.91-1.82) and other NSAIDs (e.g. naproxen relative risk 1.53; 95% CI 1.07-2.33) were similar. 17 An updated systematic review and metaanalysis compared the adverse effects of commonly used NSAIDs and coxibs against each other and against placebo. 18 Again, rofecoxib was an outlier with much increased risk of myocardial infarction compared with both placebo (odds ratio 1.65; 95% CI 1.029-2.661) and all other agents, whether nonselective NSAIDs (odd ratio 2.155; 95% CI 1.146-4.053) or other coxibs (odds ratio 1.80; 95% CI 1.217-2.66). By contrast, the risk associated with celecoxib was not increased in relation to either placebo or other NSAIDs, including naproxen (previously regarded as the agent with the lowest risk of cardiovascular risk). The risk of stroke was actually significantly lowest with celecoxib (odds ratio 0.517; 95% CI 0.287-0.929) compared with nonselective NSAIDs. The degree of COX-2 selectivity did not relate to cardiovascular outcomes.
In response to the earlier concerns about cardiovascular toxicity, a manufacturer-supported safety study was performed (the PRECISON study), 19 comparing celecoxib with naproxen and ibuprofen in patients with either established, or at high risk of, circulatory disease. The study was designed to detect cardiovascular outcomes. The primary outcome was a composite of cardiovascular death, nonfatal myocardial infarction and nonfatal stroke. Overall, no significant difference was observed in cardiovascular outcomes between the groups (celecoxib versus naproxen hazard ratio 0.93; 95% CI 0.76-1.13 and celecoxib versus ibuprofen hazard ratio 0.85; 95% CI 0.70-1.04). GI safety was significantly better with celecoxib. Despite the size and design of the study (over 24,000 participants, mean follow up 20 months), overall event rates were rather low (i.e. celecoxib 2.3%, naproxen 2.5%, ibuprofen 2.7%) and the drop-out rate was substantial (over 30%), but overall, this study is reassuring with regards to the cardiovascular risk of celecoxib. It is important to note that the maximal celecoxib dose in this trial was limited to 200 mg daily, which is lower than the dose used in the original prelaunch study (up to 400 mg twice daily) and much lower than the dose (400-800 mg) used in the colonic adenoma prevention trial where cardiovascular events were clearly documented. 10 Concurrent aspirin, as might be expected, negates much of the GI benefit of celecoxib against gastroduodenal ulceration compared with naproxen alone. 3 One of the persisting questions has remained, what is the preferable anti-inflammatory agent in combination with cardioprotective aspirin? A study from the productive Hong Kong group has now given us an answer. In the CONCERN study, a total 514 participants who had had a peptic ulcer bleed whilst on aspirin and a NSAID and needed to continue both therapies were randomly assigned to either celecoxib (100 mg twice daily) or naproxen (500 mg twice daily) in combination with both aspirin and esomeprazole. 20 Overall, celecoxib showed clear superiority. After 18 months follow up, the cumulative rates of rebleeding were 5.6% for celecoxib and 12.3% for naproxen (hazard ratio 0.44; 95% CI 0.23-0.82). Although this study was not powered to detect a difference in cardiovascular events, no trends were observed towards increased risk with celecoxib. Previous studies have suggested that the beneficial antiplatelet effect of aspirin persists during co-therapy with celecoxib. 21 Where do these recent studies leave us? It does seem as if these data warrant a welcoming of celecoxib back further within the mainstream therapies. It is obviously important to always consider both the underlying GI and cardiovascular risks when considering using any NSAID, but the safety and efficacy data for celecoxib at modest doses of up to 200 mg daily are reassuring and probably we should consider this therapeutic approach more widely when there are concerns about GI toxicity. If clinically required in the highest risk patients, celecoxib with aspirin and a PPI seems to be the safest combination. These most recent data should also influence our interpretation of other studies: rofecoxib seems an outlier with a seemingly unique risk profile, which may have biased studies looking merely at class effects and it is important that the risks and individual benefits of individual NSAIDs and coxibs are examined. Etoricoxib is the only other remaining coxib available for oral use in many markets (although not in the USA). At present there does not seem to be the depth of data available to make any firm conclusions, compared with these recent developments with celecoxib.
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